)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Active Biotech
Active Biotech (ACTI) investor relations material
Active Biotech Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary20 Aug, 2026
Executive summary
Advanced clinical development of tasquinimod in myelofibrosis, with resumed patient enrollment in Europe and expanded US collaborations.
Laquinimod program strengthened by LION study results and ongoing strategic partnering discussions for ophthalmology indications.
Naptumomab, partnered with NeoTX, continues in phase Ib/II trials for solid tumors, showing promising safety and efficacy signals.
Financial highlights
No net sales recorded for Q2 or H1 2026.
Operating loss for Q2 2026 was SEK -10.2M (Q2 2025: -11.3M); H1 2026 operating loss was SEK -18.8M (H1 2025: -22.5M).
Loss after tax for Q2 2026 was SEK -10.1M (Q2 2025: -11.2M); H1 2026 loss after tax was SEK -18.4M (H1 2025: -22.2M).
Cash and cash equivalents at June 30, 2026, were SEK 43.9M (Dec 31, 2025: SEK 65.1M).
Research and development expenses decreased 20% year-over-year for H1 2026, reflecting lower costs as the LION study concluded.
Outlook and guidance
Focus remains on advancing tasquinimod clinical studies in myelofibrosis and securing a partner for laquinimod.
Available liquidity expected to fund operations through 2026 and into Q4 2027.
Ongoing evaluation of alternative financing sources, including partnerships.
First interim analyses for tasquinimod studies anticipated in Q1 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Active Biotech
- Advancing immunomodulatory therapies in oncology and eye disorders with strong clinical momentum.ACTI
Company presentation - Tasquinimod clinical milestones achieved, R&D costs down, and liquidity secured through 2027.ACTIQ1 2026
- Advancing immunomodulatory therapies in cancer and eye disorders with strong clinical and market momentum.ACTICompany presentation
- Advancing immunomodulatory drugs in oncology and eye disorders with strong clinical momentum.ACTICompany presentation
- Clinical progress and strengthened finances position the company for key readouts in 2026–2027.ACTIQ4 2025
- Late-stage immunomodulatory pipeline targets high-value cancer and eye disorder markets.ACTICompany Presentation
- Advanced clinical progress and SEK 70M rights issue, but going concern risk remains.ACTIQ3 2025
- Clinical milestones achieved in Q2; liquidity sufficient for 2025, but more funding needed.ACTIQ2 2025
- Clinical progress in myelofibrosis and uveitis, but urgent financing needs persist.ACTIQ3 2024
Next Active Biotech earnings date
Q3 20265 Nov, 2026
Active Biotech
Next Active Biotech earnings date
Q3 20265 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage